These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 26079148

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
    Papachristos A, Pippa N, Demetzos C, Sivolapenko G.
    Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Design of next generation antibody drug conjugates].
    Zhu GD, Fu YX.
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [Abstract] [Full Text] [Related]

  • 7. Recent advances in tumor-targeting anticancer drug conjugates.
    Jaracz S, Chen J, Kuznetsova LV, Ojima I.
    Bioorg Med Chem; 2005 Sep 01; 13(17):5043-54. PubMed ID: 15955702
    [Abstract] [Full Text] [Related]

  • 8. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
    Wolska-Washer A, Robak T.
    Drug Saf; 2019 Feb 01; 42(2):295-314. PubMed ID: 30649747
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA, Chari RV.
    Clin Cancer Res; 2011 Oct 15; 17(20):6389-97. PubMed ID: 22003066
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Metabolism of bioconjugate therapeutics: why, when, and how?
    Liu H, Bolleddula J, Nichols A, Tang L, Zhao Z, Prakash C.
    Drug Metab Rev; 2020 Feb 15; 52(1):66-124. PubMed ID: 32045530
    [Abstract] [Full Text] [Related]

  • 13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E, Fernández-Medarde A.
    Eur J Pharm Biopharm; 2015 Jun 15; 93():52-79. PubMed ID: 25813885
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Small targeted cytotoxics from DNA-encoded chemical libraries.
    Samain F, Casi G.
    Curr Opin Chem Biol; 2015 Jun 15; 26():72-9. PubMed ID: 25726911
    [Abstract] [Full Text] [Related]

  • 18. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment.
    Paulus J, Sewald N.
    J Pept Sci; 2024 Jul 15; 30(7):e3561. PubMed ID: 38382900
    [Abstract] [Full Text] [Related]

  • 19. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
    Okeley NM, Alley SC, Senter PD.
    Hematol Oncol Clin North Am; 2014 Feb 15; 28(1):13-25. PubMed ID: 24287064
    [Abstract] [Full Text] [Related]

  • 20. Interview with the Theme Issue Editors of Antibody-Drug Conjugates.
    Kulkarni A, Gukasyan H.
    Pharm Res; 2015 Nov 15; 32(11):3453-7. PubMed ID: 26337768
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.